This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (6) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kim, H. J. Articles by Arora, R. Search for Related Content PubMed PubMed Citation Articles by Kim, H. J. Articles by Arora, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Atrial Fibrillation Blood Thinners Hazardous Substances DB HEPARIN WARFARIN Social Bookmarking                         What's this?

Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril

Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ

Rohit Arora, MD

Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ

Ximelagatran, an emerging new direct, oral, fixed-dose thrombin inhibitor may offer an attractive alternate to warfarin for patients with nonvalvular atrial fibrillation. The lack of drug-to-drug interactions and need for coagulation monitoring parameters such as international normalized ratio and a short half-life make therapeutic control and withdrawal in the event of bleeding easier. The side-effect profile, including elevation of liver enzymes, may temper the clinical utility of long-term use ximelagatran.

Key Words: atrial fibrillation • anticoagulants • warfarin • direct thrombin inhibitors • ximelagatran

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 10, No. 1, 11-21 (2005)
DOI: 10.1177/107424840501000102


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?